Clinical Trials on Breast-Q

Total 14265 results

Cancer Trials Ireland

Terminated

Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer (Panthera)

Metastatic Breast Cancer | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Cancer

Ireland, Spain
National Cancer Institute (NCI)

Completed

Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Inflammatory Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative

United States
National Taiwan University Hospital

Recruiting

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Metastatic Breast Cancer | Premenopausal Breast Cancer | ER Positive Breast Cancer

Taiwan
Oslo University Hospital
Karolinska Institutet; Hoffmann-La Roche; Rigshospitalet, Denmark; Helse Stavanger... and other collaborators

Completed

Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer (ALICE)

Triple Negative Breast Cancer | Cancer, Breast

Norway, Denmark
MedSIR
MacroGenics; Seagen Inc.

Withdrawn

Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer (MARGARET)

Advanced Breast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer
McMaster University

Completed

Study to Demonstrate the Preliminary Safety and Effectiveness of IPBS in Performing MRI-Guided Targeting and Intervention of Breast Tissue in Female Patients Indicated for MRI-Guided Breast Biopsy

Breast Cancer Screening | Breast Cancer Diagnosis | MRI Guided Breast Biopsy

Canada
Masonic Cancer Center, University of Minnesota

Active, not recruiting

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

Triple Negative Breast Cancer | HER2-positive Breast Cancer | TN ER-/PR-/HER2- Breast Cancer | ERany/PRany/HER2+ Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer

United States
Wake Forest University Health Sciences
Merck Sharp & Dohme LLC

Completed

Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer (PePPy)

Male Breast Cancer | Breast - Female

United States
University of Southern California
National Cancer Institute (NCI)

Withdrawn

Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Triple-negative Breast Cancer
University of Washington
National Cancer Institute (NCI)

Terminated

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer

United States
National Cancer Institute (NCI)
National Institutes of Health (NIH)

Completed

Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer

Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
National Cancer Institute (NCI)

Terminated

Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
Stanford University
California Breast Cancer Research Program

Completed

Expanding Rural Access: Distance Delivery of Support Groups (Main Study)

Depression | Breast Cancer | Stress | Breast Cancer Non-invasive Breast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer Metastatic Breast Cancer

United States
Ana C Garrido-Castro, MD
Merck Sharp & Dohme LLC; Gilead Sciences

Active, not recruiting

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Metastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | HR-Positive Breast Cancer

United States
Emory University

Completed

Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer

Breast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of Breast | Cancer of the Breast | Human Mammary Carcinoma

United States
Emory University
Novartis

Terminated

Phase II Study of Everolimus Beyond Progression

Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Unspecified Adult Solid Tumor, Protocol Specific | HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
Jonsson Comprehensive Cancer Center
Bayer; Translational Research in Oncology-U.S. Inc. (TRIO-US)

Terminated

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Stage I Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative and other conditions

United States
The First Affiliated Hospital of Xinxiang Medical...
AstraZeneca

Recruiting

The Treatment Situation of Chinese County Population With Breast Cancer

Breast Cancer | Breast Carcinoma | Breast Tumor

China
NSABP Foundation Inc
Royal Marsden NHS Foundation Trust; Pfizer; Institute of Cancer Research, United...

Completed

A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer (PALLET)

Breast Cancer | Breast Tumors | Breast Carcinoma

United Kingdom, United States, Canada
Delphinus Medical Technologies, Inc.
University of Chicago; Boston Biomedical Associates; Reed Technical Associates...

Completed

Delphinus SoftVue™ ROC Reader Study (DMT SV RRS2)

Breast Cancer Detection | Dense Breast Parenchyma | Benign Breast Findings | Normal Breast Screening | Abnormal Breast Screening

United States
Samsung Medison
University of Rochester

Unknown

Breast Ultrasound Image Reviewed With Assistance of Deep Learning Algorithms

Breast Cancer | Breast Lesions | Breast Mass

United States
Washington University School of Medicine
National Cancer Institute (NCI); National Institutes of Health (NIH); MedImmune...

Terminated

Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | TNBC - Triple-Negative Breast Cancer | Triple-negative Breast Carcinoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Active, not recruiting

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

Triple Negative Breast Cancer | Invasive Breast Cancer | Stage IV Breast Cancer | HER2 Negative

United States
National Cancer Institute (NCI)

Completed

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | Paget Disease of the Breast | Benign Breast Neoplasm

United States
Fred Hutchinson Cancer Center
GlaxoSmithKline

Completed

Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer

Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer... and other conditions

Uganda
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Canadian Cancer Trials Group

Active, not recruiting

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Invasive Breast Carcinoma | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Lobular Breast Carcinoma | Ductal Breast Carcinoma | Tubular Breast Carcinoma | Medullary Breast Carcinoma

United States, Canada
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer

Stage I Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Cardiovascular Complications

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Vascular and Cognitive Assessments in Patients With Breast Cancer Undergoing Chemotherapy After Surgery

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Cognitive/Functional Effects | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
University of Washington
United States Department of Defense; Breast Cancer Alliance

Active, not recruiting

Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Breast Cancer | HER2 Negative Breast Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast Cancer AJCC v8 | Prognostic Stage IIIC Breast Cancer AJCC v8 | Breast Inflammatory Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer

Obesity | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer

United States
George W. Sledge Jr.
National Cancer Institute (NCI)

Completed

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2 Positive Breast Carcinoma | Stage III Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Active, not recruiting

Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness) (PTW)

Stage 0 Breast Cancer | Cancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Early-Stage Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer

United States
Adrienne G. Waks
Gilead Sciences

Recruiting

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Breast Cancer Female | Breast Cancer Metastatic | Her 2 Positive Breast Cancer

United States
Medical College of Wisconsin

Recruiting

Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer

Invasive Breast Cancer

United States
Organon and Co
Institute for Applied Economics and Health Research Aps

Completed

Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021).

Male Breast Cancer
Dompé Farmaceutici S.p.A
PRA Health Sciences

Completed

A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer (FRIDA)

Metastatic Breast Cancer

United States, Spain, Belgium, Italy, France, Czechia, Poland
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

India
German Breast Group
Pfizer

Completed

Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients (MALE)

Male Breast Cancer

Germany
Salah Azaïz Cancer Institute

Unknown

Understanding Male Breast Cancer: Salah Azaïz Cancer Institute Experience

Male Breast Cancer

Tunisia
Jose Pablo Leone
Eli Lilly and Company; Translational Breast Cancer Research Consortium (TBCRC)

Recruiting

ETHAN - ET for Male BC

Male Breast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Receptor Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
University of Colorado, Denver
Cancer League of Colorado

Withdrawn

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

Metastatic Breast Cancer | Triple Negative Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Carcinoma | PD-L1 Gene Mutation

United States
BerGenBio ASA
Merck Sharp & Dohme LLC

Terminated

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Triple Negative Breast Cancer | Inflammatory Breast Cancer Stage IV

Spain, United States, United Kingdom, Norway

Clinical Trials on Breast-Q

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations